Gilead Sciences, Inc. (0QYQ.IL)
Develops medicines for HIV, hepatitis, cancer, and other serious diseases
$134.00-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+19.2%
The outlook
Gilead Sciences is trading at $134, sitting above both its 50-day and 200-day moving averages. The stock is positioned midway through its 52-week range. Analyst sentiment leans bullish overall, though the trailing P/E of 30.8 reflects a premium valuation relative to current earnings.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range52% of the way from its 52-week low to high
Market cap
$166.97B
52-wk high
$157.79
52-wk low
$108.50
50-day avg
$129.67
200-day avg
$132.00
Trailing P/E
30.8